The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| AXOGEN INC | COM | 05463X106 | 27,588 | 1,276,645 | SH | SOLE | 1,276,645 | 0 | 0 | ||
| BIOVENTUS | COM CL A | 09075A108 | 212,902 | 12,096,702 | SH | SOLE | 12,096,702 | 0 | 0 | ||
| CATALYST BIOSCIENCES INC | COM NEW | 14888D208 | 340 | 78,622 | SH | SOLE | 78,622 | 0 | 0 | ||
| EYEPOINT PHARMACEUTICALS INC | COM NEW | 30233G209 | 37,676 | 4,190,921 | SH | SOLE | 4,190,921 | 0 | 0 | ||
| MEDICINOVA INC | COM NEW | 58468P206 | 4,700 | 1,105,941 | SH | SOLE | 1,105,941 | 0 | 0 | ||
| MIMEDX GROUP, INC. | COM | 602496101 | 292,442 | 23,376,623 | SH | SOLE | 23,376,623 | 0 | 0 | ||
| REVANCE THERAPEUTICS INC | COM | 761330109 | 37,277 | 1,333,692 | SH | SOLE | 1,333,692 | 0 | 0 | ||
| TELA BIO, INC. | COM | 872381108 | 25,455 | 1,580,089 | SH | SOLE | 1,580,089 | 0 | 0 | ||
| VENUS CONCEPT, INC. | COM | 92332W105 | 38,620 | 12,417,856 | SH | SOLE | 12,417,856 | 0 | 0 | ||